Samsung Launches New AI-Enabled OB/GYN Ultrasound System
The HERA W10 Elite ultrasound platform provides enhanced visualization features and artificial intelligence (AI)-aided measurement capabilities.
Could the HERA W10 Elite reinvent ultrasound imaging in obstetrics and gynecology care?
The newly launched ultrasound system offers 2D and 3D visualization of microcirculatory and slow blood with the Advanced MV-Flow™ feature and a large organic light-emitting diode (OLED) display that provides improved characterization of diverse ultrasound images, according to Samsung, the manufacturer of the HERA W10 Elite system.
Samsung said the HERA W10 Elite also has HeartAssist™, an artificial intelligence (AI)-enhanced feature that provides automated measurement views to facilitate diagnosis of the fetal heart.
(Editor’s note: For related content, see “Adjunctive AI Software for Cardiac Ultrasound Gets FDA Nod” and “Emerging Trends in AI, Ultrasound and OB/GYN Care.”)
Other planned features, pending 510(k) clearance from the Food and Drug Administration (FDA), include a new EV2-12 transducer that allows imaging of the fetal heart and brain starting at eight weeks and Biometry Assist™, which allows one-click measurement of fetal growth parameters.
“Women’s health is a fast-growing field that requires state-of-the-art equipment for patient care. The HERA W10 Elite will bring visionary change to obstetrics and gynecology with sophisticated image processing and an ergonomic-friendly design,” noted Tracy Bury, Women’s Health Ultrasound Business Leader with Boston Imaging, the United States headquarters for Samsung’s digital radiography and ultrasound business.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
